Xvivo Perfusion AB (Xvivo Perfusion AB) Long-Term Capital Lease Obligation : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB Long-Term Capital Lease Obligation?

Xvivo Perfusion AB's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.

Xvivo Perfusion AB's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($2.06 Mil) but then declined from Dec. 2023 ($2.06 Mil) to Mar. 2024 ($0.00 Mil).

Xvivo Perfusion AB's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.17 Mil) to Dec. 2022 ($0.43 Mil) and increased from Dec. 2022 ($0.43 Mil) to Dec. 2023 ($2.06 Mil).

Xvivo Perfusion AB Long-Term Capital Lease Obligation Historical Data

The historical data trend for Xvivo Perfusion AB's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Long-Term Capital Lease Obligation Chart

Xvivo Perfusion AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.23

0.39

0.17

0.43

2.06

Xvivo Perfusion AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	2.06	-

Xvivo Perfusion AB (OTCPK:XVIPF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Xvivo Perfusion AB Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Xvivo Perfusion AB (Xvivo Perfusion AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

XVIVO:Sweden 3XV:Germany

Address

Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.